Scientists use world's fastest supercomputer to create the largest HIV evolutionary tree Oct 28, 2009
"At this scale we can begin to figure out the relationships between chronic and acute infections using statistics to determine the interconnecting branches and it is these interconnections where a specially-designed vaccine might be most effective. ###The goal of CHAVI, established by the National Institute of Allergy and Infectious diseases, is to solve major problems in HIV vaccine development and design. About Roadrunner, the world's fastest supercomputer, first to break the petaflop... (EurekAlert!)
* US will face H1N1 vaccine shortage, official says Oct 28, 2009
I dont think we will get to the original goal of 195 million influenza A(H1N1) vaccine doses delivered during the US governments fall vaccination campaign, said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. But he tempered that the government may obtain 140 million to 150 million doses, which quite frankly I think will likely be enough because we dont anticipate more than half of the people want to get vaccinated. (Taipei Times, Taiwan -- World)
USF studies H1N1 flu vaccine Oct 27, 2009
The studies are sponsored and funded by the National Institute of Allergy and Infectious Diseases and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, both part of the National Institutes of Health. Investigators plan to vaccinate about 130 HIV-infected women and 140 HIV-infected children and young adults around the country. (Tampa Bay Business Journal, FL)
US faces shortage of 55 million H1N1 flu vaccine doses Oct 27, 2009
" onclick="Next();" src="/images/butt_next. "If we get to 150 million, we will likely have as much as anybody needs," Fauci told AFP.. (Channelnewsasia.com)
Brisk Walk Can Help Leave Common Cold Behind Oct 26, 2009
The U.S. National Institute of Allergy and Infectious Diseases has more about. Copyright. (Atlanta Journal-Constitution -- Health)
Africa: Understanding How Thai Vaccine Worked is Priority Oct 23, 2009
This was the urging of one of the world's greatest AIDS researchers, Dr Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases (NIAID), at the close of the Paris AIDS Vaccine Conference yesterday (Thurs). The modest immune protection of recent Thai vaccine - the first vaccine ever to show any effect against AIDS -- must be "maximised", urged Fauci. (allAfrica.com)
Full Results of AIDS Vaccine Trial Confirm Modest Benefit Oct 22, 2009
"I don't want to use a word like 'breakthrough,' but I don't think there's any doubt that this is a very important result," Dr. Anthony S. Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, one of the trial's sponsors, told The New York Times last month. "For more than 20 years now, vaccine trials have essentially been failures," he said. (MEDLINEplus)
The AIDS Vaccine: Modest Results, but a Sign of Hope Oct 22, 2009
Detailed simultaneously on Tuesday at the Paris meeting and in a paper in the New England Journal of Medicine, the U.S. government sponsored trial (both the National Institute of Allergy and Infectious Diseases and the U.S. Army provided funding) involved about 16,400 Thai volunteers. Half were given six injections comprising two AIDS vaccines, each of which had proven ineffective on its own in previous studies; the other half of the study group was given a placebo. (Time.com)
AIDS-vaccine trial results discounted Oct 21, 2009
The trial, sponsored largely by the National Institute of Allergy and Infectious Diseases, combined two different vaccines, each of which had individually proved ineffective in previous trials, in the hope that one would prime the immune system and the second would boost immunity. The key difference between the two types of analyses is that the original one excluded seven patients who were found to have HIV infections at the time the study began. (AZCentral -- News)
Detailed Results from RV 144 HIV Vaccine Trial Published Today in The New England Journal of Medicine and Presented at the AIDS Vaccine 2009 Conference Provide Insight for Future Research Oct 20, 2009
" According to the collaborating partners, the prime-boost combination of ALVAC HIV and AIDSVAX B/E appeared to lower the rate of HIV infection by 31.2 percent compared to placebo based on the modified intent-to-treat (mITT) population (n=51 vs. n=74, respectively; p=0.04). There was no effect on the amount of virus in the blood of the study volunteers who received either vaccine or placebo and subsequently became infected with HIV. "Experts are interpreting the results and planning additional... (Canada Newswire)
Science study: Teacher participation in Columbia program improves student achievement in science Oct 17, 2009
Columbia's Summer Research Program has been supported by the Howard Hughes Medical Institute, Ambrose Monel, Braitmayer, Bristol Myers Squibb, Camille and Henry Dreyfus, Greenwald, Mellam Family, J.P. Morgan, and NY Times Company Foundations; the Charles Edison Fund, and Hebrew Technical Institute; the National Institute of Allergy and Infectious Diseases and the National Center for Research Resources Science Education Partnerships Awards of the National Institutes of Health, National Science... (EurekAlert!)
Two Swine Flu Shots for Kids Under 10 Likely Oct 16, 2009
The new Sanofi results back up what government tests are showing, said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases. For younger children, the protection from one shot is "modest but not sufficient to allow for one dose to do the trick," he said. (Newsmax)
Not taking swine flu vaccine is risky Oct 15, 2009
But Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, said that charge is false. "The H1N1 vaccine is made in exactly the same way, using the same materials, the same companies, the same process as the seasonal flu vaccine we make every single year and give to tens and tens of millions of people," Fauci said. (Casper Star-Tribune, WY)
Many Americans Still Leery of Swine Flu Vaccine Oct 14, 2009
"The H1N1 vaccine is made in exactly the same way, using the same material, the same companies, the same process as the seasonal flu vaccine we make every single year and give to tens and tens of millions of people," said Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases. Fauci explained that even the seasonal flu vaccine is changed slightly each year, with slightly different strains. (Atlanta Journal-Constitution -- Health)
Researchers question AIDS vaccine results Oct 12, 2009
But the National Institute of Allergy and Infectious Diseases, which largely funded the $120-million trial, hoped that it would provide some insight into the kinds of biological responses that must be provoked by a vaccine for it to provide protection. The researchers subsequently have been criticized for how they released the results, but they say that they feared the results would be leaked before they presented them and that they hoped to pre-empt such an event. (Honolulu Advertiser)
Frozen Assets: Decades-old Frozen Infant Stool Samples Provide Clues To Norovirus Evolution Oct 12, 2009
11, 2009) A search through decades-old frozen infant stool samples has yielded rich dividends for scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The team customized a laboratory technique to screen thousands of samples for norovirus, a major cause of acute gastroenteritis outbreaks in people of all ages. (Science Daily)
NIH Launches 2009 H1N1 Influenza Vaccine Trials In HIV-infected Pregnant Women Oct 12, 2009
The International Maternal Pediatric Adolescent AIDS Clinical Trials Group is conducting the studies, which are sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), both part of the National Institutes of Health. "These studies are important because HIV infection and pregnancy both increase the risk for a poor immune response to the normal 15-microgram dose of... (Science Daily)
Emory to conduct H1N1 vaccine trial in asthma sufferers Oct 10, 2009
The study is co-sponsored by the National Institute of Allergy and Infectious Diseases and the National Heart, Lung and Blood Institute, both are part of the National Institutes of Health. People with underlying conditions, such as asthma, are at greater risk of developing complications from the disease. (Atlanta Journal-Constitution -- Metro)
Swine Flu May Bring Surge in Hospitalizations Oct 9, 2009
Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, said the findings did not surprise him. "What we've already experienced in the spring and what we're experiencing now is that the [H1N1] virus had a predilection to infect young people and, when you look at people who required hospitalization because of complications, it's disproportionately weighted towards pregnant women and the very young and those with underlying conditions that compromise the... (Atlanta Journal-Constitution -- Health)
Doxycycline for Mansonella perstans Infection Oct 8, 2009
From the Faculty of Medicine, Pharmacy and Odontostomatology, University of Bamako (Y.I.C., B.D., A.A.D., S.S.D., S.Y.C., S.K., D.A.D., D.Y., O.K.D., S.F.T.); the Center for Disease Control (A.K.T.); and the Department of Radiology, Hospital at Point G (A.D. Keita) all in Bamako, Mali; and the Biostatistics and Research Branch (E.M.L., M.P.F.) and Laboratory of Parasitic Diseases (J.K., T.B.N., A.D. Klion), National Institute of Allergy and Infectious Diseases, National Institutes of Health,... (New England Journal of Medicine)
Early Results: In Children, 2009 H1N1 Influenza Vaccine Works Like Seasonal Flu Vaccine Oct 5, 2009
5, 2009) Early results from a trial testing a 2009 H1N1 influenza vaccine in children look promising, according to the trial sponsor, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Preliminary analysis of blood samples from a small group of trial participants shows that a single 15-microgram dose of a non-adjuvanted 2009 H1N1 influenza vaccine the same dose that is in the seasonal flu vaccine generates an immune response that is... (Science Daily)
The shot heard 'round the world: Patient trials in Thailand produce most effective AIDS vaccine to date Oct 5, 2009
"For over two decades we have been trying to discover something that can help cure or prevent AIDS," said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, one of the sponsors of the trial. "This is a major breakthrough and although only a minimal number of patients were aided, this small step is very beneficial and gives hope on further research.". (Daily Orange, NY)
Cleveland BioLabs keeps cashing in Oct 1, 2009
6 million federal contract through the Department of Health and Human Services with the Biomedical Advanced Research and Development Authority (BARDA); and a $458,512 grant from the National Institute of Allergy and Infectious Diseases ... 3 million federal stimulus grant from the National Institute of Allergy and Infectious Diseases to begin a clinical program for cancer treatment using its Protectan CBLB502. (Buffalo Business First, NY)
Africa: Successful HIV Vaccine Study Will Lead to Further Research Oct 1, 2009
The study, which began in October 2003, was conducted by the Thai Ministry of Public Health with funding and support from the U.S. Army's Walter Reed Army Institute of Research and the U.S. National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health based in Washington. The principal investigator was Dr. Supachai Rerks-Ngarm of the Thai Ministry of Public Health's Department of Disease Control. (allAfrica.com)
U.S. to Start Testing Swine Flu Vaccines in Children Sep 30, 2009
The National Institute of Allergy and Infectious Diseases said it would soon start two trials of Sanofi-Aventis' vaccine in children aged 6 months to 17 years old. "The safety monitoring committee reviewed data from more than 500 healthy adult and elderly volunteers enrolled in three ... trials of candidate H1N1 vaccines that began August 7, 2009," the NIAID, part of the National Institutes of Health, said in a statement. (MEDLINEplus)
More cancer funds for Cleveland BioLabs Sep 30, 2009
The Buffalo-based biomedical firm this week announced it was awarded a Grand Opportunities (GO) grant under the American Recovery and Reinvestment Act from the National Institute of Allergy and Infectious Diseases, part of the ... 6 million federal contract through the Department of Health and Human Services with the Biomedical Advanced Research and Development Authority (BARDA); and a $458,512 grant from the National Institute of Allergy and Infectious Diseases. (Buffalo Business First, NY)
Younger Children Need Two Doses of H1N1 Vaccine Sep 30, 2009
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said young children will likely need to have their doses 21 days apart. But he said they could receive seasonal flu shots and H1N1 shots on the same day something that could ease the logistics of vaccinating children multiple times. (Newsmax)
Nontuberculous Mycobacteria Lung Disease On The Rise In The United States, Study Finds Sep 26, 2009
A research team led by epidemiologists from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, analyzed hospital discharge records of patients in 11 states whose combined total population represents 42 percent of the country. They reviewed database records spanning 1998 to 2005, and identified more than 16,475 hospitalizations associated with pulmonary NTM in people without AIDS. Before the widespread availability of combination antiretroviral... (Science Daily)
Experimental AIDS Vaccine Delivers Good News Sep 26, 2009
"I don't want to use a word like 'breakthrough,' but I don't think there's any doubt that this is a very important result," Dr. Anthony S. Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, one of the trial's sponsors, told The New York Times ... In addition to the two vaccine patent holders and the U.S. National Institute of Allergy and Infectious Diseases, participants in the Thai trial included the United States Army, and the Thai Ministry of Public Health, the... (MEDLINEplus)
Vaccine helps prevent HIV Sep 26, 2009
He helped lead the study for the U.S. Army, which sponsored it with the National Institute of Allergy and Infectious Diseases. The institute s director, Dr. Anthony Fauci, warned that this is not the end of the road, but he said he was surprised and very pleased by the outcome. (Columbia Daily Herald, TN)
One swine flu shot enough for pre-teens, teens: trials Sep 25, 2009
National Institute of Allergy and Infectious Diseases. Anthony Fauci. (Yahoo News -- Pharmaceutical Industry News)
AIDS breakthrough as vaccine cuts infections for first time Sep 25, 2009
"These new findings represent an important step forward in HIV vaccine research," said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, which provided major funding and logistical support for the study. But a top AIDS scientist, France's Jean-Francois Delfraissy, warned that the results were "good news but the effect remains modest". (Yahoo! Asia News)
Timeline dampens euphoria over HIV vaccine Sep 25, 2009
After 26 years, they have finally made progress on demonstrating the feasibility of an HIV vaccine, said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which largely funded the $120 million study. But "is it a vaccine that is ready for prime time? No.". (AZCentral -- News)
HIV Vaccine Regimen Demonstrates Modest Preventive Effect In Thailand Clinical Study Sep 25, 2009
"These new findings represent an important step forward in HIV vaccine research," says Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, which provided major funding and other support for the study. "For the first time, an investigational HIV vaccine has demonstrated some ability to prevent HIV infection among vaccinated individuals. Additional research is needed to better understand how this vaccine regimen reduced the risk... (Science Daily)
Hope Found in First Vaccine to Stop HIV Sep 25, 2009
The army was one of the partners on the trial, along with the Thai Ministry of Public Health, the National Institute of Allergy and Infectious Diseases, Sanofi Pasteur, and Global Solutions for Infectious Diseases. "We are very excited and pleased with the outcome of this trial and congratulate all those who participated in it," Schoomaker said in a statement. (ABC News)
Experimental vaccine shows promise with AIDS Sep 25, 2009
The study was sponsored by the U.S. Army and the National Institute of Allergy and Infectious Diseases. Doctors say the vaccine is not efficient enough yet to be rolled out to the public. (WWLTV.com, LA)
Successful AIDS-Vaccine Trial Raises Hopes — and Questions Sep 25, 2009
"The efficacy is a modest one. But it's the first time we've seen a positive signal of efficacy in a human trial of any HIV vaccine. That's an exciting result in a field that has been characterized by disappointments for two decades," says Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), which provided major funding and other support for the Thai trial. The scientists working on the trial, led in Thailand by the U.S. Army and the Thailand Ministry of... (Time.com)
After 20 years, AIDS vaccine shows success in trials Sep 25, 2009
"There's no doubt that this is a very important result. Conceptually, we now know a vaccine is possible," said Dr Anthony S Fauci, director of the National Institute of Allergy and Infectious Diseases. The most confusing aspect of the trial, according to Dr Fauci, is that everyone who did become infected developed roughly the same amount of virus in their blood whether they got the vaccine or a placebo. (India Times, India)
HIV vaccine: All you wanted to know Sep 25, 2009
The trial cost $105 million and was mostly paid for by the U.S. National Institute of Allergy and Infectious Diseases, one of the National Institutes of Health. The U.S. Army paid for 25 percent of it. (India Times, India)
XOMA to Develop Therapeutic Antibody for H1N1 and H5N1 Influenza Viruses Under $2.2 Million U.S. Government Program Managed by SRI International Sep 24, 2009
The subcontract will be funded through the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health ... This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN266200600011C / N01-AI-60011. (Primezone Releases)
HIV Vaccine Study First to Show Some Effectiveness in Preventing HIV Sep 24, 2009
Collaborating partners on this study, referred to as RV144, include the U.S. Army, the Thai Ministry of Public Health, the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, sanofi pasteur, and Global Solutions for Infectious Diseases (GSID). The collaborators are already working with external experts to determine the need for additional studies on this vaccine regimen and consider the impact of this study's findings on other HIV vaccine candidates. (PR Newswire)
Sars patients can provide therapy Sep 24, 2009
A team from the US National Institute of Allergy and Infectious Diseases then tested the most effective of these antibodies in mice and found they prevented the virus from multiplying in the respiratory system. Dr Lanzavecchia said: "At present there is no immunological treatment for Sars, and a vaccine may take several years to produce. "Our approach produces protective antibodies that would provide immediate protection against the Sars virus. (Yahoo News -- SARS)
NEW AIDS VACCINE Sep 24, 2009
"Myself, like others, did not think there was a very high chance that this would give any degree of efficacy," said Dr. Anthony Fauci of the U.S. National Institute of Allergy and Infectious Diseases, which helped pay for the study. "But nonetheless, we went ahead with the trial and it was controversial to go ahead with it.". (AlertNet)
County: we are prepared for swine flu Sep 24, 2009
"These findings suggest that people alive during the 1918 influenza pandemic have the most protection against the current 2009 H1N1 influenza virus because of their prior exposure," the National Institute of Allergy and Infectious Diseases' Web site says. Thompson emphasizes the county doesn't want to scare anyone, likely the reason officials haven't discussed the 1918 strain with the public. (Chetek Alert, WI)
NIH ups ClevelandBioLabs research Sep 23, 2009
was awarded the $458,512 grant from the National Institute of Allergy and Infectious Diseases for advanced studies using its Protectan CBLB502 in the mitigation of radiation damage. The public company (NASDAQ: CBLI) previously received $774,183 under the grant. (Buffalo Business First, NY)
2 swine-flu inoculations necessary for younger kids Sep 22, 2009
However, older children between the ages of 10 and 17 appear to have a "robust immune response" after the first inoculation, meaning they only need one shot, officials with the National Institute of Allergy and Infectious Diseases said. The news is not completely unexpected, as young children typically need a second shot of the regular seasonal flu vaccine the first time they are immunized. (AZCentral -- News)
Study: Tots need booster for swine flu shot Sep 22, 2009
"As we had hoped, in children the 2009 H1N1 vaccine is acting like seasonal flu vaccine," says Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which sponsored the study. "The response in young children is less robust, but this is not unexpected.". (Honolulu Advertiser)
1 Swine Flu Shot Enough for Older Kids Sep 22, 2009
"The initial results are encouraging," Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, said during a press conference. "As we had hoped, in children the 2009 H1N1 vaccine is acting just like the seasonal flu vaccine.". (Atlanta Journal-Constitution -- Health)
A (H1N1): Children under 10 need 2 doses of vaccine Sep 22, 2009
Early trials show that younger children are not having a robust immune reaction to the A/H1N1 flu vaccine, and that they would likely need to have their doses 21 days apart, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told reporters in a telephone briefing. Protection kicks in for older children within eight to 10 days of the shot, just like it does for adults, Fauci said. (The Star Online, Malaysia)
One swine flu shot enough for pre-teens, teens: trials Sep 22, 2009
National Institute of Allergy and Infectious Diseases. Anthony Fauci. (Yahoo News -- Pharmaceutical Industry News)
Clinical trial of antiretroviral-based HIV prevention strategies for women now under way Sep 17, 2009
"We need multiple, scientifically proven HIV prevention strategies acceptable to different populations to effectively combat the spread of the virus, and PrEP and microbicides are two promising approaches that we are actively pursuing," says Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID). "The VOICE study is designed to answer multiple crucial questions about these experimental interventions, with an emphasis on protecting women from HIV.". (EurekAlert! -- Business News)
Nearly 1 million doses of H1N1 vaccine to arrive in Arizona Sep 16, 2009
The National Institute of Allergy and Infectious Diseases said Friday that the vaccine is safe. Getting ready. (AZCentral)
Weighing Costs, Benefits Of HIV Treatments Sep 16, 2009
Chief sponsors of the trial are the National Institute of Allergy and Infectious Diseases (NIAID) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Findings also revealed that the LPV/r arm of the trial showed results so much better that in the spring of 2009, an independent data and safety monitoring board (DSMB) halted the NVP arm and gave the go-ahead for IMPAACT to enroll children who did not receive NVP at birth. (Science Daily)
Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Enhance Efficiency and Scale-up of its Malaria Vaccine Manufacturing Process Sep 16, 2009
Sept. 16 /PRNewswire-USNewswire/ -- Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The award for two years is $1. (PR Newswire)
NexBio(R) Presents DAS181 (Fludase(R)*) Potently Inhibits Novel Swine-Origin A(H1N1) and NAI-Resistant Influenza Viruses, at ICAAC 2009 Sep 14, 2009
The DAS181 development program is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, under BAA Contract HHSN266200600015C and grant U01-AI070281. ViradinTM, invented and developed by NexBio, is a parenteral protein under development, currently at lead optimization stage, directed to the treatment of viral hemorrhagic fevers and bacterial biothreat sepsis. (PR Newswire)
Early Results From Clinical Trials Of 2009 H1N1 Influenza Vaccines In Healthy Adults Sep 14, 2009
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, also is conducting clinical trials of 2009 H1N1 influenza vaccines, produced by Sanofi Pasteur and CSL Limited. The NIAID trials are testing two different dosages (15 micrograms versus 30 micrograms) and evaluating the immune response to one and two doses of these vaccines. (Science Daily)
Swine Flu Trials Continue to Point to 1-Dose Vaccine Sep 12, 2009
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said the vaccine trials involving pregnant women are just starting and results are not expected until late October. "Children are lagging behind the adult trial so we will get some preliminary data in about two weeks on the children," he added. (Atlanta Journal-Constitution -- Health)
One shot enough against swine flu, US studies confirm Sep 12, 2009
"Preliminary data from our trials indicate that a single 15-microgram dose of ... vaccine is well tolerated and induces an immune response in most healthy adults," said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health (NIH). Results of NIH-sponsored clinical trials which began last month showed that a swine flu vaccine produced by French pharmaceutical giant Sanofi Pasteur produced "a robust immune response" in 96 percent... (Yahoo! Asia News)
Pregnant Women Taking Part In New H1N1 Vaccination Trials Sep 11, 2009
"In everybody's list of who should be vaccinated, pregnant women are right at the top," says Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), the study's sponsor. The study will involve up to 120 women 18 to 39 years of age who are in their second or third trimester of pregnancy. (W-USA News, DC)
Swine flu vaccine: Should you get it when time comes? Sep 9, 2009
Given that history and the distrust that it bred, Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases since 1984, understands the public's concern. He told us that a risk-benefit analysis is always done with vaccinations. (Juneau Empire)
Swine Flu Vaccine Seems Safe: Experts Sep 6, 2009
"There have been no red flags at all," Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, told HealthDay. A trial designed to test the vaccine on healthy adults began on Aug. 7, while another trial involving children started Aug. 18. (Atlanta Journal-Constitution -- Health)
Fresh targets give hope for HIV vaccine Sep 5, 2009
"If a vaccine can elicit neutralizing antibodies like the ones discovered here, it would have a strong chance of being effective," says John Mascola, a virologist at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, who was not involved in the study. To date, two potential HIV have been tested -- and failed -- in human clinical trials. (Scientific American)
Swine Flu May Be Less Dangerous Than Predicted: Study Sep 2, 2009
Another hopeful sign that the swine flu pandemic might be milder than predicted came last month from two infectious-disease experts at the U.S. National Institute of Allergy and Infectious Diseases. Drs. (Atlanta Journal-Constitution -- Health)
H1N1 Pandemic Virus Does Not Mutate Into 'Superbug' In Lab Study Sep 2, 2009
The research is funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Adapted from materials provided by. (Science Daily)
UTMB Begins Swine Flu Vaccine Trial Aug 29, 2009
GALVESTON, Texas -- The University of Texas Medical Branch at Galveston was selected by the National Institute of Allergy and Infectious Diseases to conduct pediatric vaccine trials for the H1N1 (swine flu) virus. The trials begin Friday. (Click2Houston, TX)
